-
1
-
-
0035012803
-
The epidemiology of rheumatoid arthritis
-
Gabriel, S. E. The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 27, 269-282 (2001).
-
(2001)
Rheum. Dis. Clin. North Am.
, vol.27
, pp. 269-282
-
-
Gabriel, S.E.1
-
2
-
-
0031732074
-
The longterm outcome of rheumatoid arthritis. Work disability: A prospective 18 year study of 816 patients
-
Wolfe, F. E. & Hawley, D. J. The longterm outcome of rheumatoid arthritis. Work disability: a prospective 18 year study of 816 patients. J. Rheumatol. 25, 2108-2117 (1998).
-
(1998)
J. Rheumatol.
, vol.25
, pp. 2108-2117
-
-
Wolfe, F.E.1
Hawley, D.J.2
-
3
-
-
0028105830
-
Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures
-
Pincus, T. E., Brooks, R. H. & Callahan, L. F. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures Ann. Intern. Med. 120, 26-34 (1994).
-
(1994)
Ann. Intern. Med.
, vol.120
, pp. 26-34
-
-
Pincus, T.E.1
Brooks, R.H.2
Callahan, L.F.3
-
4
-
-
0033001678
-
An assessment of the annual and long-term direct costs: The impact of poor function and functional decline
-
Yelin, E. & Wanke, L. A. An assessment of the annual and long-term direct costs: the impact of poor function and functional decline. Arthritis Rheum. 42, 1209-1218 (1999).
-
(1999)
Arthritis Rheum.
, vol.42
, pp. 1209-1218
-
-
Yelin, E.1
Wanke, L.A.2
-
5
-
-
0034062017
-
The costs of rheumatoid arthritis: An international long-term view
-
Pugner, K. M., Scott, D. I., Holmes, J. W. & Hieke, K. The costs of rheumatoid arthritis: an international long-term view. Semin. Arthritis Rheum. 29, 305-320 (2000).
-
(2000)
Semin. Arthritis Rheum.
, vol.29
, pp. 305-320
-
-
Pugner, K.M.1
Scott, D.I.2
Holmes, J.W.3
Hieke, K.4
-
6
-
-
0028813226
-
Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity
-
Smolen, J. S. et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum. 38, 38-43 (1995).
-
(1995)
Arthritis Rheum.
, vol.38
, pp. 38-43
-
-
Smolen, J.S.1
-
7
-
-
84861808622
-
Epidemiology and genetics of rheumatoid arthritis
-
Silman, A. J. & Pearson, J. E. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 4 (Suppl 3), S268-S272 (2002).
-
(2002)
Arthritis Res.
, vol.4
, Issue.SUPPL. 3
-
-
Silman, A.J.1
Pearson, J.E.2
-
8
-
-
0012964271
-
HLA molecules, bacteria and autoimmunity
-
Ebringer, A. & Wilson, C. HLA molecules, bacteria and autoimmunity. J. Med. Microbial. 49, 305-311 (2000).
-
(2000)
J. Med. Microbial.
, vol.49
, pp. 305-311
-
-
Ebringer, A.1
Wilson, C.2
-
9
-
-
0034984010
-
From reactive arthritis to rheumatoid arthritis
-
Toivanen, P. From reactive arthritis to rheumatoid arthritis. J. Autoimmun 16, 369-371 (2001).
-
(2001)
J. Autoimmun.
, vol.16
, pp. 369-371
-
-
Toivanen, P.1
-
10
-
-
0024604643
-
Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis
-
van der Heijde D. M. et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1, 1036-1038 (1989).
-
(1989)
Lancet
, vol.1
, pp. 1036-1038
-
-
van der Heijde, D.M.1
-
11
-
-
0014816759
-
The treatment of rheumatoid arthritis and necrotizing vasculitis with penicillamine
-
Jaffe, I. A. The treatment of rheumatoid arthritis and necrotizing vasculitis with penicillamine. Arthritis Rheum. 13, 436-443 (1970).
-
(1970)
Arthritis Rheum.
, vol.13
, pp. 436-443
-
-
Jaffe, I.A.1
-
12
-
-
0028280174
-
Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial
-
Kloppenburg, M. A. et al. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum. 37, 629-636 (1994).
-
(1994)
Arthritis Rheum.
, vol.37
, pp. 629-636
-
-
Kloppenburg, M.A.1
-
13
-
-
0036056315
-
Toll-like receptors: A family of pattern-recognition receptors in mammals
-
REVIEWS3011
-
Armant, M. A. & Fenton, M. J. Toll-like receptors: a family of pattern-recognition receptors in mammals. Genome Biol. 3, REVIEWS3011 (2002).
-
(2002)
Genome Biol.
, vol.3
-
-
Armant, M.A.1
Fenton, M.J.2
-
14
-
-
0036067659
-
Toll receptors, CD14, and macrophage activation and deactivation by LPS
-
Dobrovolskaia M. A. & Vogel, S. N. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes. Infect. 4, 903-914 (2002).
-
(2002)
Microbes. Infect.
, vol.4
, pp. 903-914
-
-
Dobrovolskaia, M.A.1
Vogel, S.N.2
-
15
-
-
0242356668
-
-
(eds Smolen, J. S. & Lipsky, P. E.), (Martin Dunitz, London-New York)
-
Romagnani, S., Matucci, A. & Rossi, O. in Targeted Therapies in Rheumatology (eds Smolen, J. S. & Lipsky, P. E.), 317-328 (Martin Dunitz, London-New York, 2003).
-
(2003)
Targeted Therapies in Rheumatology
, pp. 317-328
-
-
Romagnani, S.1
Matucci, A.2
Rossi, O.3
-
16
-
-
0034756143
-
Rheumatoid arthritis is more than cytokines: Autoimmunity and rheumatoid arthritis
-
Smolen, J. S. & Steiner, G. Rheumatoid arthritis is more than cytokines: autoimmunity and rheumatoid arthritis. Arthritis Rheum. 44, 2218-2220 (2001).
-
(2001)
Arthritis Rheum.
, vol.44
, pp. 2218-2220
-
-
Smolen, J.S.1
Steiner, G.2
-
17
-
-
0012663097
-
Autoantibodies in rheumatoid arthritis and their clinical significance
-
Steiner, G. & Smolen, J. S. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res. 4, S1-S5 (2002).
-
(2002)
Arthritis Res.
, vol.4
-
-
Steiner, G.1
Smolen, J.S.2
-
18
-
-
20244368182
-
Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis
-
Fritsch, R. et al. Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J. Immunol. 169, 1068-1076 (2002).
-
(2002)
J. Immunol.
, vol.169
, pp. 1068-1076
-
-
Fritsch, R.1
-
19
-
-
0031974911
-
Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies
-
Schellekens, G. A., de Jong, B. A. W., van den Hoogen, F. H. J., van de Putte, L. B. A. & van Venrooj, W. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 101, 273-281 (1998).
-
(1998)
J. Clin. Invest.
, vol.101
, pp. 273-281
-
-
Schellekens, G.A.1
de Jong, B.A.W.2
van den Hoogen, F.H.J.3
van de Putte, L.B.A.4
van Venrooj, W.5
-
20
-
-
0036188754
-
Whole-genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom
-
MacKay, K. et al. Whole-genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom. Arthritis Rheum. 413, 632-639 (2002).
-
(2002)
Arthritis Rheum.
, vol.413
, pp. 632-639
-
-
MacKay, K.1
-
21
-
-
0032703306
-
Cytokine production by synovial T cells in rheumatoid arthritis
-
Steiner, G. et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 38, 202-213 (1999).
-
(1999)
Rheumatology (Oxford)
, vol.38
, pp. 202-213
-
-
Steiner, G.1
-
22
-
-
0030021790
-
The role of T-lymphocytes and cytokines in rheumatoid arthritis
-
Smolen, J. S. et al. The role of T-lymphocytes and cytokines in rheumatoid arthritis. Scand. J. Rheumatol. 25, 1-4 (1996).
-
(1996)
Scand. J. Rheumatol.
, vol.25
, pp. 1-4
-
-
Smolen, J.S.1
-
24
-
-
0030459439
-
Shift toward T lymphocytes T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis
-
Dolhain, R. J. et al. Shift toward T lymphocytes T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum. 39, 1961-1969 (1996).
-
(1996)
Arthritis Rheum.
, vol.39
, pp. 1961-1969
-
-
Dolhain, R.J.1
-
25
-
-
0030459439
-
Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis
-
Dolhain, R. J. et al. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum. 39, 1961-1969 (1996).
-
(1996)
Arthritis Rheum.
, vol.39
, pp. 1961-1969
-
-
Dolhain, R.J.1
-
26
-
-
0033168136
-
Altered memory T cell differentiation in patients with early rheumatoid arthritis
-
Skapenko, A. et al. Altered memory T cell differentiation in patients with early rheumatoid arthritis. J. Immunol. 163, 491-499 (1999).
-
(1999)
J. Immunol.
, vol.163
, pp. 491-499
-
-
Skapenko, A.1
-
28
-
-
0027465503
-
Cell surface glycoproteins expressed on activated human T cells induce production of interleukin 1 beta by monocytes: A possible role of CD69
-
Isler, P., Vey, E., Zhang, J. H. & Dayer, J. M. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin 1 beta by monocytes: a possible role of CD69. Eur. Cytokine Netw. 4, 15-23 (1993),
-
(1993)
Eur. Cytokine Netw.
, vol.4
, pp. 15-23
-
-
Isler, P.1
Vey, E.2
Zhang, J.H.3
Dayer, J.M.4
-
29
-
-
0031042456
-
Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis
-
McInnes, I. B., Leung, B. P., Sturrock, R. D., Field, M. & Liew, F. Y. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nature Med. 3, 189-195 (1997).
-
(1997)
Nature Med.
, vol.3
, pp. 189-195
-
-
McInnes, I.B.1
Leung, B.P.2
Sturrock, R.D.3
Field, M.4
Liew, F.Y.5
-
30
-
-
0027240829
-
Macrophage activation by T cells: Cognate and non-cognate signals
-
Stout, R. D. Macrophage activation by T cells: cognate and non-cognate signals. Curr. Opin. Immunol. 5, 398-403 (1993).
-
(1993)
Curr. Opin. Immunol.
, vol.5
, pp. 398-403
-
-
Stout, R.D.1
-
31
-
-
0032055597
-
IL-17 stimulates the production of proinflammatory cytokines, IL-1 beta and TNF-alpha, by human macrophages
-
Jovanovic, D. V. et al. IL-17 stimulates the production of proinflammatory cytokines, IL-1 beta and TNF-alpha, by human macrophages. J. Immunol. 160, 3513-3521 (1998).
-
(1998)
J. Immunol.
, vol.160
, pp. 3513-3521
-
-
Jovanovic, D.V.1
-
32
-
-
0030980394
-
T-lymphocyte-fibroblast interactions
-
Crowston, J. G., Salmon, M., Khaw, P. T. & Akbar, A. N. T-lymphocyte-fibroblast interactions. Biochem. Soc. Trans 25, 529-531 (1997).
-
(1997)
Biochem. Soc. Trans.
, vol.25
, pp. 529-531
-
-
Crowston, J.G.1
Salmon, M.2
Khaw, P.T.3
Akbar, A.N.4
-
33
-
-
0027486150
-
Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines
-
Bombara, M. P. et al. Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines. J. Leukoc. Biol. 54, 399-406 (1993).
-
(1993)
J. Leukoc. Biol.
, vol.54
, pp. 399-406
-
-
Bombara, M.P.1
-
34
-
-
0017325645
-
Collagenase production by rheumatoid synovial cells: Stimulation by a human lymphocyte factor
-
Dayer, J. M., Graham, R., Russel, G. & Krane, S. M. Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science 181-183 (1977).
-
(1977)
Science
, vol.195
, pp. 181-183
-
-
Dayer, J.M.1
Graham, R.2
Russel, G.3
Krane, S.M.4
-
35
-
-
0023694150
-
Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis
-
Eastgate, J. A. et al. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 2, 706-709 (1988).
-
(1988)
Lancet
, vol.2
, pp. 706-709
-
-
Eastgate, J.A.1
-
36
-
-
0025255530
-
Quantitative analysis of cytokine gene expression in rheumatoid arthritis
-
Firestein, G. S., Alvaro-Gracia, J. M. & Maki, R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 144, 3347-3353 (1990).
-
(1990)
J. Immunol.
, vol.144
, pp. 3347-3353
-
-
Firestein, G.S.1
Alvaro-Gracia, J.M.2
Maki, R.3
-
37
-
-
0022606130
-
Interleukin-1 lymphocyte chemotactic activity in rheumatoid arthritis synovial fluid
-
Miossec, P., Dinarello, C. A. & Ziff, M. Interleukin-1 lymphocyte chemotactic activity in rheumatoid arthritis synovial fluid. Arthritis Rheum. 29, 461-470 (1986).
-
(1986)
Arthritis Rheum.
, vol.29
, pp. 461-470
-
-
Miossec, P.1
Dinarello, C.A.2
Ziff, M.3
-
38
-
-
0030903094
-
The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis
-
Okamoto, H. et al. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum.40, 1096-1105 (1997).
-
(1997)
Arthritis Rheum.
, vol.40
, pp. 1096-1105
-
-
Okamoto, H.1
-
39
-
-
0023712236
-
Detection of tumor-necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum
-
Saxne, T., Palladino, M. A. Jr, Heinegard, D., Talal, N. & Woliheim, F. A. Detection of tumor-necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 31, 1041-1045 (1988).
-
(1988)
Arthritis Rheum.
, vol.31
, pp. 1041-1045
-
-
Saxne, T.1
Palladino Jr., M.A.2
Heinegard, D.3
Talal, N.4
Woliheim, F.A.5
-
40
-
-
0026091413
-
Localization of tumor-necrosis factor-alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis
-
Chu, C. Q., Field, M., Feldmann, M. & Maini, R. N. Localization of tumor-necrosis factor-alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34, 1125-1132 (1991).
-
(1991)
Arthritis Rheum.
, vol.34
, pp. 1125-1132
-
-
Chu, C.Q.1
Field, M.2
Feldmann, M.3
Maini, R.N.4
-
41
-
-
0024314554
-
Inhibitory effect of TNF-alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
-
Brennan, F. M., Chantry, D., Jackson, A., Maini, R. & Feldmann, M. Inhibitory effect of TNF-alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2, 244-247 (1989).
-
(1989)
Lancet
, vol.2
, pp. 244-247
-
-
Brennan, F.M.1
Chantry, D.2
Jackson, A.3
Maini, R.4
Feldmann, M.5
-
42
-
-
0022472749
-
Tumor necrosis factor (cachectin) is an endogeneous pyrogen and induces production of interleukin 1
-
Dinarello C. A. et al. Tumor necrosis factor (cachectin) is an endogeneous pyrogen and induces production of interleukin 1. J. Exp. Med. 163, 1433-1450 (1986).
-
(1986)
J. Exp. Med.
, vol.163
, pp. 1433-1450
-
-
Dinarello, C.A.1
-
43
-
-
0036839148
-
Role of interleukin 15 and interleukin 18 in inflammatory response
-
Liew, F. Y. & McInnes, I. B. Role of interleukin 15 and interleukin 18 in inflammatory response. Ann. Rheum. Dis. 61 S2, ii100-ii102 (2002).
-
(2002)
Ann. Rheum. Dis.
, vol.61
, Issue.S2
-
-
Liew, F.Y.1
McInnes, I.B.2
-
44
-
-
0242388249
-
-
Smolen J. S. & Lipsky, P. L. (eds) (Dunitz, London)
-
Folkman J. in Targeted Therapies in Rheumatology Smolen J. S. & Lipsky, P. L. (eds) 111-131 (Dunitz, London, 2003).
-
(2003)
Targeted Therapies in Rheumatology
, pp. 111-131
-
-
Folkman, J.1
-
45
-
-
0036009115
-
NF-κB at the crossroads of life and death
-
Karin, M. & Lin, A. NF-κB at the crossroads of life and death. Nature Immunol. 3, 221-227 (2002).
-
(2002)
Nature Immunol.
, vol.3
, pp. 221-227
-
-
Karin, M.1
Lin, A.2
-
46
-
-
0036098552
-
AP-1 as a regulator of cell life and death
-
Shaulian, E. & Karin, M. AP-1 as a regulator of cell life and death. Nature Cell Biol. 4, 131-136 (2002).
-
(2002)
Nature Cell Biol.
, vol.4
, pp. 131-136
-
-
Shaulian, E.1
Karin, M.2
-
47
-
-
0242293746
-
-
Smolen, J. S. & Lipsky, P. E. (eds) (Martin Dunitz, London-New York)
-
Aringer, M., Watford, W. & O'Shea, J. J. in Targeted Therapies in Rheumatology Smolen, J. S. & Lipsky, P. E. (eds) 404-420 (Martin Dunitz, London-New York, 2003).
-
(2003)
Targeted Therapies in Rheumatology
, pp. 404-420
-
-
Aringer, M.1
Watford, W.2
O'Shea, J.J.3
-
48
-
-
0037280317
-
Novel mechanistic concepts for the control of leukocyte transmigration: Specialization of integrins, chemokines, and junctional molecules
-
Weber, C. Novel mechanistic concepts for the control of leukocyte transmigration: specialization of integrins, chemokines, and junctional molecules. J. Mol. Med. 81, 4-19 (2003).
-
(2003)
J. Mol. Med.
, vol.81
, pp. 4-19
-
-
Weber, C.1
-
49
-
-
0028227917
-
Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis
-
Zvaifler, N. J. & Firestein, G. S. Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum. 37, 783-789 (1994).
-
(1994)
Arthritis Rheum.
, vol.37
, pp. 783-789
-
-
Zvaifler, N.J.1
Firestein, G.S.2
-
50
-
-
0031894140
-
Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis
-
Gravallese, E. M. et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 152, 943-951 (1998).
-
(1998)
Am. J. Pathol.
, vol.152
, pp. 943-951
-
-
Gravallese, E.M.1
-
51
-
-
0034284970
-
Bone resorption by osteoclasts
-
Teitelbaum, S. L. Bone resorption by osteoclasts. Science 289, 1504-1508 (2000).
-
(2000)
Science
, vol.289
, pp. 1504-1508
-
-
Teitelbaum, S.L.1
-
52
-
-
0036853902
-
Osteoclasts are essential for TNF-α-mediated joint destruction
-
Redlich, K. et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J. Clin. Invest. 110, 1419-1427 (2002).
-
(2002)
J. Clin. Invest.
, vol.110
, pp. 1419-1427
-
-
Redlich, K.1
-
53
-
-
0036226744
-
Local production of complement proteins in rheumatoid arthritis synovium
-
Neumann, E. et al. Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 46, 934-945 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
, pp. 934-945
-
-
Neumann, E.1
-
54
-
-
0016817748
-
Electron microscopic demonstration of immunoglobulin deposition in rheumatoid cartilage
-
Ishikawa, H., Smiley, J. D. & Ziff, M, Electron microscopic demonstration of immunoglobulin deposition in rheumatoid cartilage. Arthritis Rheum. 18, 563-576 (1975).
-
(1975)
Arthritis Rheum.
, vol.18
, pp. 563-576
-
-
Ishikawa, H.1
Smiley, J.D.2
Ziff, M.3
-
55
-
-
0034192427
-
Induction and suppression of collagen-induced arthritis is dependent on distinct Fcγ receptors
-
Kleinau S., Martinsson, P. & Heyman, B. Induction and suppression of collagen-induced arthritis is dependent on distinct Fcγ receptors. J. Exp. Med. 191, 1611-1616 (2000).
-
(2000)
J. Exp. Med.
, vol.191
, pp. 1611-1616
-
-
Kleinau, S.1
Martinsson, P.2
Heyman, B.3
-
56
-
-
0036307544
-
Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity
-
Elenkov, I. J. & Chrousos, G. P. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann. N. Y. Acad Sci. 966, 290-303 (2002).
-
(2002)
Ann. N. Y. Acad Sci.
, vol.966
, pp. 290-303
-
-
Elenkov, I.J.1
Chrousos, G.P.2
-
57
-
-
0034811016
-
Control of autoimmunity by regulatory T cells
-
Shevach, E. M. et al. Control of autoimmunity by regulatory T cells. Adv. Exp. Med. Biol. 490, 21-32 (2001).
-
(2001)
Adv. Exp. Med. Biol.
, vol.490
, pp. 21-32
-
-
Shevach, E.M.1
-
58
-
-
0030066368
-
Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis
-
ten Wolde, S. et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 347, 347-352 (1996).
-
(1996)
Lancet
, vol.347
, pp. 347-352
-
-
ten Wolde, S.1
-
59
-
-
0030963885
-
Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation
-
ten Wolde, S., Hermans, J., Breedveld, F. C. & Dijkmans, B. A. Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. Ann. Rheum. Dis. 56, 235-239 (1997).
-
(1997)
Ann. Rheum. Dis.
, vol.56
, pp. 235-239
-
-
ten Wolde, S.1
Hermans, J.2
Breedveld, F.C.3
Dijkmans, B.A.4
-
60
-
-
84960582159
-
Efficacy of methotrexate in rheumatoid arthritis
-
Weinblatt, M. E. Efficacy of methotrexate in rheumatoid arthritis. Br. J. Rheumatol. 34, S43-S48 (1995).
-
(1995)
Br. J. Rheumatol.
, vol.34
-
-
Weinblatt, M.E.1
-
61
-
-
0034735827
-
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
-
Bathon, J. M. et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343, 1586-1593 (2000).
-
(2000)
N. Engl. J. Med.
, vol.343
, pp. 1586-1593
-
-
Bathon, J.M.1
-
62
-
-
0033053835
-
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
-
Smolen, J. S. et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 353, 259-266 (1999).
-
(1999)
Lancet
, vol.353
, pp. 259-266
-
-
Smolen, J.S.1
-
63
-
-
0033557695
-
Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression
-
Manna, S. K. & Aggarwal, B. B. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression. J. Immunol. 162, 2095-2102 (1999).
-
(1999)
J. Immunol.
, vol.162
, pp. 2095-2102
-
-
Manna, S.K.1
Aggarwal, B.B.2
-
64
-
-
0032519992
-
Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production
-
Siemasko, K. F. et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J. Immunol. 160, 1581-1588 (1998).
-
(1998)
J. Immunol.
, vol.160
, pp. 1581-1588
-
-
Siemasko, K.F.1
-
65
-
-
0025080342
-
Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts
-
Wolfe, F., Hawley, D. J. & Cathey, M. A. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J. Rheumatol. 17, 994-1002 (1990).
-
(1990)
J. Rheumatol.
, vol.17
, pp. 994-1002
-
-
Wolfe, F.1
Hawley, D.J.2
Cathey, M.A.3
-
66
-
-
0036021133
-
Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study
-
Aletaha, D. & Smolen, J. S. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J. Rheumatol. 29, 1631-1638 (2002).
-
(2002)
J. Rheumatol.
, vol.29
, pp. 1631-1638
-
-
Aletaha, D.1
Smolen, J.S.2
-
67
-
-
0036902026
-
The rheumatoid arthritis patient in the clinic: Comparing more than 1300 consecutive DMARD courses
-
Aletaha, D. & Smolen, J. S. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology (Oxford) 41, 1367-1374 (2002).
-
(2002)
Rheumatology (Oxford)
, vol.41
, pp. 1367-1374
-
-
Aletaha, D.1
Smolen, J.S.2
-
68
-
-
0029869174
-
The effectiveness of early treatment with 'second-line' antirheumatic drugs: A randomized, controlled trial
-
van der Heide, A. et al. The effectiveness of early treatment with 'second-line' antirheumatic drugs: a randomized, controlled trial. Ann. Intern. Med. 124, 699-707 (1996).
-
(1996)
Ann. Intern. Med.
, vol.124
, pp. 699-707
-
-
van der Heide, A.1
-
69
-
-
0142107711
-
The benefit of very early refferal and therapy with disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis
-
Nell, V. et al. The benefit of very early refferal and therapy with disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis. Arthritis Rheum. 49, S334 (2002).
-
(2002)
Arthritis Rheum.
, vol.49
-
-
Nell, V.1
-
70
-
-
0030751946
-
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalizine alone in early rheumatoid arthritis: A randomised trial
-
Boers, M. et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalizine alone in early rheumatoid arthritis: a randomised trial. Lancet 350, 309-318 (1997).
-
(1997)
Lancet
, vol.350
, pp. 309-318
-
-
Boers, M.1
-
71
-
-
0033535754
-
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial
-
FIN-RACo trial group
-
Mottonen, T. et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353, 1568-1573 (1999).
-
(1999)
Lancet
, vol.353
, pp. 1568-1573
-
-
Mottonen, T.1
-
72
-
-
9244247260
-
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
-
O'Dell, J. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334, 1287-1291 (1996).
-
(1996)
N. Engl. J. Med.
, vol.334
, pp. 1287-1291
-
-
O'Dell, J.1
-
73
-
-
0032957015
-
Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
-
Dougados, M. et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann. Rheum. Dis. 58, 220-225 (1999).
-
(1999)
Ann. Rheum. Dis.
, vol.58
, pp. 220-225
-
-
Dougados, M.1
-
74
-
-
0027946325
-
The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis
-
Felson, D. T., Anderson, J. J. & Meenan, R. F. The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. Arthritis Rheum. 37, 1487-1491 (1994).
-
(1994)
Arthritis Rheum.
, vol.37
, pp. 1487-1491
-
-
Felson, D.T.1
Anderson, J.J.2
Meenan, R.F.3
-
75
-
-
0030696346
-
Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial
-
Haagsma, C. J., van Riel, P. L., de Jong, A. J. & van de Putte, L. B. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial, Br. J. Rheumatol. 36, 1082-1088 (1997).
-
(1997)
Br. J. Rheumatol.
, vol.36
, pp. 1082-1088
-
-
Haagsma, C.J.1
van Riel, P.L.2
de Jong, A.J.3
van de Putte, L.B.4
-
76
-
-
0032693752
-
Combination DMARD therapy including corticosteroids in early rheumatoid arthritis
-
Mottonen, T. T., Hannonen, P. J. & Boers, M. Combination DMARD therapy including corticosteroids in early rheumatoid arthritis. Clin. Exp. Rheumatol. 17, S59-S65 (1999).
-
(1999)
Clin. Exp. Rheumatol.
, vol.17
-
-
Mottonen, T.T.1
Hannonen, P.J.2
Boers, M.3
-
77
-
-
0036833533
-
Pharmacological management of early rheumatoid arthritis - Does combination therapy improve outcomes?
-
Dougados, M. & Smolen, J. S. Pharmacological management of early rheumatoid arthritis - does combination therapy improve outcomes? J. Rheumatol. 66, S20-S26 (2002).
-
(2002)
J. Rheumatol.
, vol.66
-
-
Dougados, M.1
Smolen, J.S.2
-
78
-
-
0029022389
-
Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis
-
The Methotrexate-Cyclosporine Combination Study Group
-
Tugwell, P. et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N. Engl. J. Med. 333, 137-141 (1995).
-
(1995)
N. Engl. J. Med.
, vol.333
, pp. 137-141
-
-
Tugwell, P.1
-
79
-
-
0037027427
-
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial
-
Kremer, J. M. et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 137, 726-733 (2002).
-
(2002)
Ann. Intern. Med.
, vol.137
, pp. 726-733
-
-
Kremer, J.M.1
-
80
-
-
0031660364
-
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
-
Maini, R. N. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552-1563 (1998).
-
(1998)
Arthritis Rheum.
, vol.41
, pp. 1552-1563
-
-
Maini, R.N.1
-
81
-
-
0035056003
-
Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned?
-
Feldmann, M. & Maini, R. N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19, 163-196 (2001).
-
(2001)
Annu. Rev. Immunol.
, vol.19
, pp. 163-196
-
-
Feldmann, M.1
Maini, R.N.2
-
82
-
-
0026039673
-
Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
-
Keffer, J. et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025-4031 (1991).
-
(1991)
EMBO J.
, vol.10
, pp. 4025-4031
-
-
Keffer, J.1
-
83
-
-
0028143211
-
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
-
Elliott, M. J. et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105-1110 (1994).
-
(1994)
Lancet
, vol.344
, pp. 1105-1110
-
-
Elliott, M.J.1
-
84
-
-
0034735842
-
Infliximab and methotrexate in the treatment of rheumatoid arthritis
-
Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
-
Lipsky, P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343, 1594-1602 (2000).
-
(2000)
N. Engl. J. Med.
, vol.343
, pp. 1594-1602
-
-
Lipsky, P.E.1
-
85
-
-
0033611472
-
A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
-
Weinblatt, M. E. et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340, 253-259 (1999).
-
(1999)
N. Engl. J. Med.
, vol.340
, pp. 253-259
-
-
Weinblatt, M.E.1
-
86
-
-
0013511183
-
Treatment of rheumatoid arthritis with recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
-
Moreland, L. W. et al. Treatment of rheumatoid arthritis with recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141-147 (1997).
-
(1997)
N. Engl. J. Med.
, vol.337
, pp. 141-147
-
-
Moreland, L.W.1
-
87
-
-
0037231533
-
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
-
Weinblatt, M. E. et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum, 48, 35-45 (2003).
-
(2003)
Arthritis Rheum.
, vol.48
, pp. 35-45
-
-
Weinblatt, M.E.1
-
88
-
-
0033768473
-
Update on D2E7: A fully human anti-tumour necrosis factor alpha monoclonal antibody
-
Kempeni, J. Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody. Ann. Rheum. Dis. 59 S1, i44-i45 (2000).
-
(2000)
Ann. Rheum. Dis.
, vol.59
, Issue.S1
-
-
Kempeni, J.1
-
89
-
-
0036838681
-
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)
-
Furst, D. E. et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann. Rheum. Dis. 61 S2, ii2-ii7 (2002).
-
(2002)
Ann. Rheum. Dis.
, vol.61
, Issue.S2
-
-
Furst, D.E.1
-
90
-
-
0035846326
-
Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent
-
Keane, J. et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N. Engl. J. Med. 345, 1098-1104 (2001).
-
(2001)
N. Engl. J. Med.
, vol.345
, pp. 1098-1104
-
-
Keane, J.1
-
91
-
-
0035674613
-
Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides
-
Mohan, N. et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 44, 2862-2869 (2001).
-
(2001)
Arthritis Rheum.
, vol.44
, pp. 2862-2869
-
-
Mohan, N.1
-
92
-
-
0031943254
-
Interleukin-1 receptor antagonist: Role in biology
-
Arend, W. P., Malyak, M., Gurthridge, C. J. & Gabay, C. Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol. 16, 27-55 (1998).
-
(1998)
Annu. Rev. Immunol.
, vol.16
, pp. 27-55
-
-
Arend, W.P.1
Malyak, M.2
Gurthridge, C.J.3
Gabay, C.4
-
93
-
-
0034677123
-
Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice
-
Horai, R. et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191, 313-320(2000).
-
(2000)
J. Exp. Med.
, vol.191
, pp. 313-320
-
-
Horai, R.1
-
94
-
-
17444394445
-
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
-
Bresnihan, B. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum.41, 2196-2204 (1998).
-
(1998)
Arthritis Rheum.
, vol.41
, pp. 2196-2204
-
-
Bresnihan, B.1
-
95
-
-
0036190776
-
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial
-
Cohen, S. et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 614-624 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
, pp. 614-624
-
-
Cohen, S.1
-
96
-
-
0034083128
-
A multicenter, double-blind, dose-ranging, randomized, placebo- controlled study of recombinant human interleukin-1 receptor antagonist inpatients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores
-
Jiang, Y. et al. A multicenter, double-blind, dose-ranging, randomized, placebo- controlled study of recombinant human interleukin-1 receptor antagonist inpatients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43, 1001-1009 (2000).
-
(2000)
Arthritis Rheum.
, vol.43
, pp. 1001-1009
-
-
Jiang, Y.1
-
97
-
-
1842602667
-
Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: Different profiles in trauma and rheumatoid arthritis
-
Konttinen, Y. T. et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann. Rheum. Dis. 68, 691-697 (1999).
-
(1999)
Ann. Rheum. Dis.
, vol.68
, pp. 691-697
-
-
Konttinen, Y.T.1
-
98
-
-
0035694399
-
Metalloproteases and inhibitors in arthritic diseases
-
Martel-Pelletier, J., Welsch, D. J. & Pelletier, J. P. Metalloproteases and inhibitors in arthritic diseases. Best. Pract. Res. Clin. Rheumatol. 15, 805-829 (2001).
-
(2001)
Best. Pract. Res. Clin. Rheumatol.
, vol.15
, pp. 805-829
-
-
Martel-Pelletier, J.1
Welsch, D.J.2
Pelletier, J.P.3
-
99
-
-
0035129903
-
ADAMTS: A novel family of extracellular matrix proteases
-
Tang, B. L. ADAMTS: a novel family of extracellular matrix proteases. Int. J. Biochem. Cell Biol. 33, 33-44 (2001).
-
(2001)
Int. J. Biochem. Cell Biol.
, vol.33
, pp. 33-44
-
-
Tang, B.L.1
-
100
-
-
0031874213
-
Collagen mimetics
-
Goodman, M., Bhumralkar, Jefferson. E. A., Kwak, J. & Locardi, E. Collagen mimetics. Biopolymers 47, 127-142 (1998).
-
(1998)
Biopolymers
, vol.47
, pp. 127-142
-
-
Goodman, M.1
Bhumralkar, A.2
Jefferson, E.A.3
Kwak, J.4
Locardi, E.5
-
101
-
-
0035819527
-
Development of matrix metalloprotainase inhibitors in cancer therapy
-
Hidalgo, M. & Eckhardt, S. G. Development of matrix metalloprotainase inhibitors in cancer therapy. J. Natl Cancer Inst. 93, 178-193 (2001).
-
(2001)
J. Natl. Cancer Inst.
, vol.93
, pp. 178-193
-
-
Hidalgo, M.1
Eckhardt, S.G.2
-
102
-
-
0034770450
-
Matrix metalloprotainase inhibitors in rheumatic diseases
-
Close, D. R. Matrix metalloprotainase inhibitors in rheumatic diseases. Ann. Rheum. Dis. 60 S3, iii62-iii67 (2001).
-
(2001)
Ann. Rheum. Dis.
, vol.60
, Issue.S3
-
-
Close, D.R.1
-
103
-
-
0036838574
-
Treatments no longer in development for rheumatoid arthritis
-
Keystone, E. Treatments no longer in development for rheumatoid arthritis. Ann. Rheum. Dis. 61 S2, ii43-ii45 (2002).
-
(2002)
Ann. Rheum. Dis.
, vol.61
, Issue.S2
-
-
Keystone, E.1
-
104
-
-
0034615550
-
Tissue inhibitors of metalloproteinases; evolution, structure and function
-
1477
-
Brew, K., Dinakarpandian, D. & Nagase, H. Tissue inhibitors of metalloproteinases; evolution, structure and function. Biochim. Biophys. Acta 1477, 267-283 (2000).
-
(2000)
Biochim. Biophys. Acta
, pp. 267-283
-
-
Brew, K.1
Dinakarpandian, D.2
Nagase, H.3
-
105
-
-
0035676661
-
Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice
-
Schett, G. et al. Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice. Arthritis Rheum. 44, 2888-2898 (2001).
-
(2001)
Arthritis Rheum.
, vol.44
, pp. 2888-2898
-
-
Schett, G.1
-
106
-
-
8044257704
-
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
-
Black, R. A. et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385, 729-733 (1997).
-
(1997)
Nature
, vol.385
, pp. 729-733
-
-
Black, R.A.1
-
107
-
-
0034903680
-
Tumor necrosis factor-α (TNF-α) converting enzyme contributes to production of TNF-α in synovial tissues from patients with rheumatoid arthritis
-
Ohta, S. et al. Tumor necrosis factor-α (TNF-α) converting enzyme contributes to production of TNF-α in synovial tissues from patients with rheumatoid arthritis. J. Rheumatol. 28, 1756-1763 (2001).
-
(2001)
J. Rheumatol.
, vol.28
, pp. 1756-1763
-
-
Ohta, S.1
-
108
-
-
0036082365
-
(E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl -2'- (methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase
-
Beck, G. et al. (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl -2'- (methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase. J. Pharmacol. Exp. Ther. 302, 390-396 (2002).
-
(2002)
J. Pharmacol. Exp. Ther.
, vol.302
, pp. 390-396
-
-
Beck, G.1
-
109
-
-
0034883069
-
Inhibition of tumor necrosis factor-alpha (TNF-α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-α-converting enzyme and matrix metalloproteinases
-
Conway, J. G, et al. Inhibition of tumor necrosis factor-alpha (TNF-α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-α-converting enzyme and matrix metalloproteinases. J. Pharmacol. Exp. Ther. 298, 900-908 (2001).
-
(2001)
J. Pharmacol. Exp. Ther.
, vol.298
, pp. 900-908
-
-
Conway, J.G.1
-
110
-
-
26544468999
-
Development of a novel dual TACE/MMP inhibitor for treatment of RA
-
Zhang, Y. et al. Development of a novel dual TACE/MMP inhibitor for treatment of RA, Arthritis Rheum. 46, S136 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
-
-
Zhang, Y.1
-
111
-
-
0034775522
-
Biology of TACE inhibition
-
Newton, R. C. et al. Biology of TACE inhibition. Ann. Rheum.Dis. 60 S3, iii25-iii32 (2001).
-
(2001)
Ann. Rheum.Dis.
, vol.60
, Issue.S3
-
-
Newton, R.C.1
-
112
-
-
17944381638
-
Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation
-
Ruuls, S. R. et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 15, 533-543 (2001).
-
(2001)
Immunity
, vol.15
, pp. 533-543
-
-
Ruuls, S.R.1
-
113
-
-
0030698766
-
A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling
-
Alexopoulou, L., Pasparakis, M. & Kollias, G. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling, Eur. J. Immunol. 27, 2588-2592 (1997).
-
(1997)
Eur. J. Immunol.
, vol.27
, pp. 2588-2592
-
-
Alexopoulou, L.1
Pasparakis, M.2
Kollias, G.3
-
114
-
-
0029891449
-
Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF α processing in RA synovial membrane cell cultures
-
Williams, L. M. et al. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF α processing in RA synovial membrane cell cultures J. Clin. Invest. 97, 2833-2841 (1996).
-
(1996)
J. Clin. Invest.
, vol.97
, pp. 2833-2841
-
-
Williams, L.M.1
-
115
-
-
0026507126
-
A novel heterodimeric cysteine protease is required for interleukin-1 β processing in monocytes
-
Thornberry, N. A. et al. A novel heterodimeric cysteine protease is required for interleukin-1 β processing in monocytes. Nature 356, 768-774 (1992).
-
(1992)
Nature
, vol.356
, pp. 768-774
-
-
Thornberry, N.A.1
-
116
-
-
0032194115
-
Generation of biologically active IL-1 β by matrix metalloproteinases: A novel caspase-1-independent pathway of IL-1 β processing
-
Schonbeck, U., Mach, F. & Libby, P. Generation of biologically active IL-1 β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 β processing. J. Immunol. 161, 3340-3346 (1998).
-
(1998)
J. Immunol.
, vol.161
, pp. 3340-3346
-
-
Schonbeck, U.1
Mach, F.2
Libby, P.3
-
117
-
-
0032521457
-
Interleukin-18 regulation of interferon gamma production and cell proliferation as shown in interleukin-1β converting enzyme (caspase-1)-deficient mice
-
Fantuzzi, G., Puren, A. J., Harding, M. W., Livingston, D. J. & Dinarello, C. A. Interleukin-18 regulation of interferon gamma production and cell proliferation as shown in interleukin-1β converting enzyme (caspase-1)-deficient mice. Blood 91, 2118-2125 (1998).
-
(1998)
Blood
, vol.91
, pp. 2118-2125
-
-
Fantuzzi, G.1
Puren, A.J.2
Harding, M.W.3
Livingston, D.J.4
Dinarello, C.A.5
-
118
-
-
0032031392
-
Post-translational processing of murine IL-1: Evidence that ATP-induced release of IL-1α and IL-1β occurs via a similar mechanism
-
Perregaux, D. G. & Gabel, C. A. Post-translational processing of murine IL-1: evidence that ATP-induced release of IL-1α and IL-1β occurs via a similar mechanism. J. Immunol. 160, 2460-2477 (1998).
-
(1998)
J. Immunol.
, vol.160
, pp. 2460-2477
-
-
Perregaux, D.G.1
Gabel, C.A.2
-
119
-
-
0034929774
-
ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs
-
Randle, J. C., Harding, M. W., Ku, G., Schonharting, M. & Kurrle, R. ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert. Opin. Investig. Drugs 10, 1207-1209 (2001).
-
(2001)
Expert. Opin. Investig. Drugs
, vol.10
, pp. 1207-1209
-
-
Randle, J.C.1
Harding, M.W.2
Ku, G.3
Schonharting, M.4
Kurrle, R.5
-
120
-
-
0029971948
-
Interleukin-1β converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice
-
Ku, G., Faust, T., Lauffer, L. L., Livingston, D. J. & Harding, M. W. Interleukin-1β converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine 8, 377-386 (1996).
-
(1996)
Cytokine
, vol.8
, pp. 377-386
-
-
Ku, G.1
Faust, T.2
Lauffer, L.L.3
Livingston, D.J.4
Harding, M.W.5
-
121
-
-
0242388248
-
Clinical effects of pralnacasan (PRAL), an orally-active interleukin-1β converting enzyme (ICE) inhibitor, in a 285 patient Phil trial in rheumatoid arthritis (RA)
-
Pavelka, K. et al. Clinical effects of pralnacasan (PRAL), an orally-active interleukin-1β converting enzyme (ICE) inhibitor, in a 285 patient Phil trial in rheumatoid arthritis (RA). Abstr. Am. Coll. Rheumatol. 66th Ann. Sci. Meet. (2002).
-
(2002)
Abstr. Am. Coll. Rheumatol. 66th Ann. Sci. Meet.
-
-
Pavelka, K.1
-
122
-
-
0036899591
-
Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP
-
Dell'Antonio, G., Quattrini, A., Cin, E. D., Fulgenzi, A. & Ferrero, M. E. Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum. 46, 3378-3385 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
, pp. 3378-3385
-
-
Dell'Antonio, G.1
Quattrini, A.2
Cin, E.D.3
Fulgenzi, A.4
Ferrero, M.E.5
-
123
-
-
0037096207
-
Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response
-
Labasi, J. M. et al. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J. Immunol. 168, 6436-6445 (2002).
-
(2002)
J. Immunol.
, vol.168
, pp. 6436-6445
-
-
Labasi, J.M.1
-
124
-
-
0034084163
-
Phosphorylation meets ubiquination: The control of NF-κB activity
-
Karin, M. & Ben-Neriah, Y. Phosphorylation meets ubiquination: the control of NF-κB activity. Annu. Rev. Immunol. 18, 621-663 (2000).
-
(2000)
Annu. Rev. Immunol.
, vol.18
, pp. 621-663
-
-
Karin, M.1
Ben-Neriah, Y.2
-
125
-
-
0000240724
-
-
Thompson, A. (ed.) (Academic Press, San Diego, CA)
-
Zhang, M. & Tracey, K. J. In The Cytokine Handbook. Thompson, A. (ed.) 517-548 (Academic Press, San Diego, CA, 1998).
-
(1998)
The Cytokine Handbook
, pp. 517-548
-
-
Zhang, M.1
Tracey, K.J.2
-
126
-
-
0033618337
-
Matrix metalloproteinases
-
Nagase, H. & Woessner, J. F. Matrix metalloproteinases. J. Biol. Chem. 274, 21491-21494 (1999).
-
(1999)
J. Biol. Chem.
, vol.274
, pp. 21491-21494
-
-
Nagase, H.1
Woessner, J.F.2
-
127
-
-
0032428729
-
AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis
-
Han, Z. et al. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28, 197-208 (1998).
-
(1998)
Autoimmunity
, vol.28
, pp. 197-208
-
-
Han, Z.1
-
128
-
-
0033758633
-
Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase in synovial tissue and cells in rheumatoid arthritis
-
Schett, G. et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum. 43, 2501-2512 (2000).
-
(2000)
Arthritis Rheum.
, vol.43
, pp. 2501-2512
-
-
Schett, G.1
-
129
-
-
0034887261
-
VX-745. Vertex Pharmaceuticals
-
Haddad, J. J. VX-745. Vertex Pharmaceuticals. Curr. Opin. Investig. Drugs 2, 1070-1076 (2001).
-
(2001)
Curr. Opin. Investig. Drugs
, vol.2
, pp. 1070-1076
-
-
Haddad, J.J.1
-
130
-
-
0031803059
-
SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes
-
Badger, A. M. et al. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J. Immunol. 161, 467-473 (1998).
-
(1998)
J. Immunol.
, vol.161
, pp. 467-473
-
-
Badger, A.M.1
-
131
-
-
0033578080
-
Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase
-
Liverton, N. J. et al. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. 42, 2180-2190 (1999).
-
(1999)
J. Med. Chem.
, vol.42
, pp. 2180-2190
-
-
Liverton, N.J.1
-
132
-
-
0035086636
-
The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy
-
McIay, L. M. et al. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy Bioorg. Med. Chem. 9, 537-554 (2001).
-
(2001)
Bioorg. Med. Chem.
, vol.9
, pp. 537-554
-
-
McIay, L.M.1
-
133
-
-
0032745423
-
RWJ. 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase
-
Wadsworth, S. A. et al. RWJ. 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J. Pharmacol. Exp. Ther. 291, 680-687 (1999).
-
(1999)
J. Pharmacol. Exp. Ther.
, vol.291
, pp. 680-687
-
-
Wadsworth, S.A.1
-
134
-
-
0036715931
-
Pyridinylimidazole based p38 MAP kinase inhibitors
-
Jackson, P. F. & Bullington, J. L. Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Top. Med. Chem. 2, 1011-1020 (2002).
-
(2002)
Curr. Top. Med. Chem.
, vol.2
, pp. 1011-1020
-
-
Jackson, P.F.1
Bullington, J.L.2
-
135
-
-
0035848384
-
RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency
-
Collis, A. J. et al. RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency. Bioorg. Med. Chem. Lett. 11, 693-696 (2001).
-
(2001)
Bioorg. Med. Chem. Lett.
, vol.11
, pp. 693-696
-
-
Collis, A.J.1
-
136
-
-
0037019275
-
Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate
-
Regan, J. et al. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J. Med. Chem. 45, 2994-3008 (2002).
-
(2002)
J. Med. Chem.
, vol.45
, pp. 2994-3008
-
-
Regan, J.1
-
137
-
-
18344395134
-
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
-
Pargellis, C. et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nature Struct. Biol. 9, 268-272 (2002).
-
(2002)
Nature Struct. Biol.
, vol.9
, pp. 268-272
-
-
Pargellis, C.1
-
138
-
-
0036719870
-
The non-diaryl heterocycle classes of p38 MAP kinase inhibitors
-
Cirillo, P. F., Pargellis, C. & Regan, J. The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr. Top. Med Chem. 2, 1021-1035 (2002).
-
(2002)
Curr. Top. Med Chem.
, vol.2
, pp. 1021-1035
-
-
Cirillo, P.F.1
Pargellis, C.2
Regan, J.3
-
139
-
-
0031934170
-
Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models
-
Jackson, J. R. et al. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J. Pharmacol. Exp. Ther. 284, 687-692 (1998).
-
(1998)
J. Pharmacol. Exp. Ther.
, vol.284
, pp. 687-692
-
-
Jackson, J.R.1
-
140
-
-
0035000643
-
Suppression of the clinical and cytokine response to endotoxin by RWJ- 67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers
-
Fijen, J. W. et al. Suppression of the clinical and cytokine response to endotoxin by RWJ- 67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin. Exp. Immunol. 124, 16-20 (2001).
-
(2001)
Clin. Exp. Immunol.
, vol.124
, pp. 16-20
-
-
Fijen, J.W.1
-
141
-
-
0033994234
-
Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation
-
Pirvola, U. et al. Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. J. Neurosci. 20, 43-50 (2000).
-
(2000)
J. Neurosci.
, vol.20
, pp. 43-50
-
-
Pirvola, U.1
-
142
-
-
0036844412
-
Inhibition of the c-Jun N-terminal kinase signaling pathway influences neurite outgrowth of spiral ganglion neurons in vitro
-
Bodmer, D., Gloddek, B., Ryan, A. F., Huverstuhl, J. & Brors, D. Inhibition of the c-Jun N-terminal kinase signaling pathway influences neurite outgrowth of spiral ganglion neurons in vitro. Laryngoscope 112, 2057-2061 (2002).
-
(2002)
Laryngoscope
, vol.112
, pp. 2057-2061
-
-
Bodmer, D.1
Gloddek, B.2
Ryan, A.F.3
Huverstuhl, J.4
Brors, D.5
-
143
-
-
0034931503
-
c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis
-
Han, Z. et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest. 108, 73-81 (2001).
-
(2001)
J. Clin. Invest.
, vol.108
, pp. 73-81
-
-
Han, Z.1
-
144
-
-
0036445261
-
Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A downregulates c-myc gene expression and endothelial cell proliferation
-
Pintus, G. et al. Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A downregulates c-myc gene expression and endothelial cell proliferation. Eur. J. Biochem. 269, 5861-5870 (2002).
-
(2002)
Eur. J. Biochem.
, vol.269
, pp. 5861-5870
-
-
Pintus, G.1
-
145
-
-
0036858359
-
Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury
-
Mori, T., Wang, X., Aoki, T. & Lo, E. H. Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury. J. Neurotrauma 19, 1411-1419 (2002).
-
(2002)
J. Neurotrauma
, vol.19
, pp. 1411-1419
-
-
Mori, T.1
Wang, X.2
Aoki, T.3
Lo, E.H.4
-
146
-
-
0036839571
-
Is NF-κB a useful therapeutic target in rheumatoid arthritis?
-
Feldmann, M. et al. Is NF-κB a useful therapeutic target in rheumatoid arthritis? Ann. Rheum.Dis. 61 S2, ii13-ii18 (2002).
-
(2002)
Ann. Rheum.Dis.
, vol.61
, Issue.S2
-
-
Feldmann, M.1
-
147
-
-
0035139792
-
Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
-
Yamamoto, Y. & Gaynor, R. B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer J. Clin. Invest. 107, 135-142 (2001).
-
(2001)
J. Clin. Invest.
, vol.107
, pp. 135-142
-
-
Yamamoto, Y.1
Gaynor, R.B.2
-
148
-
-
0034489187
-
Naturally occurring and synthetic inhibitors of NF-κB functions
-
Umezawa, K., Ariga, A. & Matsumoto, N. Naturally occurring and synthetic inhibitors of NF-κB functions. Anticancer Drug Des. 15, 239-244 (2000).
-
(2000)
Anticancer Drug Des.
, vol.15
, pp. 239-244
-
-
Umezawa, K.1
Ariga, A.2
Matsumoto, N.3
-
149
-
-
15844381960
-
The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-κB
-
Pahl, H. L. et al. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-κB. J. Exp. Med. 183, 1829-1840 (1996).
-
(1996)
J. Exp. Med.
, vol.183
, pp. 1829-1840
-
-
Pahl, H.L.1
-
150
-
-
0033178749
-
Essential role of T cell NF-κB activation in collagen-induced arthritis
-
Seetharaman, R., Mora, A. L., Nabozny, G., Boothby, M. & Chen, J. Essential role of T cell NF-κB activation in collagen-induced arthritis. J. Immunol. 163, 1577-1583 (1999).
-
(1999)
J. Immunol.
, vol.163
, pp. 1577-1583
-
-
Seetharaman, R.1
Mora, A.L.2
Nabozny, G.3
Boothby, M.4
Chen, J.5
-
151
-
-
0036099012
-
Gliotoxin, an inhibitor of nuclear factor-κB, attenuates peptidoglycan-polysaccharide-induced colitis in rats
-
Fitzpatrick, L. R., Wang, J. & Le, T. Gliotoxin, an inhibitor of nuclear factor-κB, attenuates peptidoglycan-polysaccharide-induced colitis in rats. Inflamm. Bowel. Dis. 8, 159-167 (2002).
-
(2002)
Inflamm. Bowel. Dis.
, vol.8
, pp. 159-167
-
-
Fitzpatrick, L.R.1
Wang, J.2
Le, T.3
-
152
-
-
0037124207
-
Pyrazolo[3, 4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck - A selectivity insight
-
Burchat, A. F. et al. Pyrazolo[3, 4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck - a selectivity insight. Bioorg. Mad. Chem. Lett. 12, 1687-1690 (2002).
-
(2002)
Bioorg. Mad. Chem. Lett.
, vol.12
, pp. 1687-1690
-
-
Burchat, A.F.1
-
153
-
-
0035124182
-
Differential regulation of CD3- and CD28-induced IL-2 and IFN-gamma production by a novel tyrosine kinase inhibitor XR774 from Cladosporium cf. cladosporioides
-
Sadeghi, R. et al. Differential regulation of CD3- and CD28-induced IL-2 and IFN-gamma production by a novel tyrosine kinase inhibitor XR774 from Cladosporium cf. cladosporioides. Int. Immunopharmacol. 1, 33-48 (2001).
-
(2001)
Int. Immunopharmacol.
, vol.1
, pp. 33-48
-
-
Sadeghi, R.1
-
154
-
-
0034654091
-
Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases
-
Yorgin, P. D. et al. Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases. J. Immunol. 164, 2915-2923 (2000).
-
(2000)
J. Immunol.
, vol.164
, pp. 2915-2923
-
-
Yorgin, P.D.1
-
155
-
-
0033117811
-
Inhibition of p56(lck) tyrosine kinase by isothiazolones
-
Trevillyan, J. M. et al. Inhibition of p56(lck) tyrosine kinase by isothiazolones. Arch. Biochem. Biophys. 364, 19-29 (1999).
-
(1999)
Arch. Biochem. Biophys.
, vol.364
, pp. 19-29
-
-
Trevillyan, J.M.1
-
156
-
-
0034837053
-
Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection
-
Kamens, J. S., Ratnofsky, S. E. & Hirst, G. C. Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection. Curr. Opin. Investig. Drugs 2, 1213-1219 (2001).
-
(2001)
Curr. Opin. Investig. Drugs
, vol.2
, pp. 1213-1219
-
-
Kamens, J.S.1
Ratnofsky, S.E.2
Hirst, G.C.3
-
157
-
-
0033607499
-
Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme
-
Matsumoto, I. et al. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286, 1732-5 (1999).
-
(1999)
Science
, vol.286
, pp. 1732-1735
-
-
Matsumoto, I.1
-
158
-
-
0027139297
-
Genes on the X chromosome affect development of collagen-induced arthritis in mice
-
Jansson, L. & Holmdahl R. Genes on the X chromosome affect development of collagen-induced arthritis in mice. Clin. Exp. Immunol. 94, 459-465 (1993).
-
(1993)
Clin. Exp. Immunol.
, vol.94
, pp. 459-465
-
-
Jansson, L.1
Holmdahl, R.2
-
159
-
-
0027399081
-
Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia
-
Tsukada, S. et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72, 279-290 (1993).
-
(1993)
Cell
, vol.72
, pp. 279-290
-
-
Tsukada, S.1
-
160
-
-
0034657235
-
Bruton's tyrosine kinase links the B cell receptor to nuclear factor κB activation
-
Bajpai, U. D., Zhang, K., Teutsch, M., Sen, R. & Wortis, H. H. Bruton's tyrosine kinase links the B cell receptor to nuclear factor κB activation. J. Exp. Med. 191, 1735-1744 (2000).
-
(2000)
J. Exp. Med.
, vol.191
, pp. 1735-1744
-
-
Bajpai, U.D.1
Zhang, K.2
Teutsch, M.3
Sen, R.4
Wortis, H.H.5
-
161
-
-
0037087438
-
Macrophage effector functions controlled by Bruton's tyrosine kinase are more crucial than the cytokine balance of T cell responses for microfilarial clearance
-
Mukhopadhyay, S. et al. Macrophage effector functions controlled by Bruton's tyrosine kinase are more crucial than the cytokine balance of T cell responses for microfilarial clearance. J. Immunol. 168, 2914-2921 (2002).
-
(2002)
J. Immunol.
, vol.168
, pp. 2914-2921
-
-
Mukhopadhyay, S.1
-
162
-
-
0033515450
-
Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 (α-cyano-β-hydroxy-β-methyl-N-(2, 5-dibromophenyl )propenamide]
-
Mahajan, S. et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 (α-cyano-β-hydroxy-β-methyl-N-(2, 5-dibromophenyl propenamide]. J. Biol. Chem. 274, 9587-9599 (1999).
-
(1999)
J. Biol. Chem.
, vol.274
, pp. 9587-9599
-
-
Mahajan, S.1
-
163
-
-
0036433208
-
Phosphorylation of Bruton's tyrosine kinase by c-Abl
-
Backesjo, C. M., Vargas, L., Superti-Furga, G. & Edvard Smith, C. I. Phosphorylation of Bruton's tyrosine kinase by c-Abl. Biochem. Biophys. Res. Commun. 299, 510-515 (2002).
-
(2002)
Biochem. Biophys. Res. Commun.
, vol.299
, pp. 510-515
-
-
Backesjo, C.M.1
Vargas, L.2
Superti-Furga, G.3
Edvard Smith, C.I.4
-
164
-
-
0038544296
-
Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumour necrosis factor α production
-
(in the press)
-
Horwood, N. J. et al. Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumour necrosis factor α production J. Exp. Med. (in the press).
-
J. Exp. Med.
-
-
Horwood, N.J.1
-
165
-
-
0035750533
-
B cell signaling. Introduction
-
Tsubata, T. & Wienands, J. B cell signaling. Introduction, Int. Rev. Immunol. 20, 675-678 (2001).
-
(2001)
Int. Rev. Immunol.
, vol.20
, pp. 675-678
-
-
Tsubata, T.1
Wienands, J.2
-
166
-
-
0036796777
-
Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A phase II double-blinded, randomized, dose-escalating trial
-
Choy, E. H. et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 41, 1133-1137 (2002).
-
(2002)
Rheumatology (Oxford)
, vol.41
, pp. 1133-1137
-
-
Choy, E.H.1
-
167
-
-
0037315157
-
Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): Results of a randomized, open-label, pilot study
-
Rutgeerts, P. et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study Aliment. Pharmacol. Ther. 17, 185-192 (2003).
-
(2003)
Aliment. Pharmacol. Ther.
, vol.17
, pp. 185-192
-
-
Rutgeerts, P.1
-
168
-
-
0036822909
-
Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis
-
Coxon, A. et al. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum. 46, 2604-2612 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
, pp. 2604-2612
-
-
Coxon, A.1
-
169
-
-
0036735138
-
Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage
-
Abramson, S. B. & Amin, A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 41, 972-980 (2002).
-
(2002)
Rheumatology (Oxford)
, vol.41
, pp. 972-980
-
-
Abramson, S.B.1
Amin, A.2
-
170
-
-
0033179534
-
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis
-
Charles, P. et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. 163, 1521-1528 (1999).
-
(1999)
J. Immunol.
, vol.163
, pp. 1521-1528
-
-
Charles, P.1
-
171
-
-
0032536542
-
Interleukin 6 is required for the development of collagen-induced arthritis
-
Alonzi, T. et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187, 461-468 (1998).
-
(1998)
J. Exp. Med.
, vol.187
, pp. 461-468
-
-
Alonzi, T.1
-
172
-
-
0027402917
-
Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody
-
Wending, D., Racadot, E. & Wijdenes, J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody J. Rheumatol.20, 259-262 (1993).
-
(1993)
J. Rheumatol.
, vol.20
, pp. 259-262
-
-
Wending, D.1
Racadot, E.2
Wijdenes, J.3
-
173
-
-
0036899812
-
Therapeutic benefit of blocking interleukin-6 activity with an anti- interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial
-
Choy, E. H. et al. Therapeutic benefit of blocking interleukin-6 activity with an anti- interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 46, 3143-3150 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
, pp. 3143-3150
-
-
Choy, E.H.1
-
174
-
-
84925549112
-
The paradigm of IL-6: From basic science to medicine
-
Naka, T., Nishimoto, N. & Kishimoto, T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 4 S3, S233-S242 (2002).
-
(2002)
Arthritis Res.
, vol.4
, Issue.S3
-
-
Naka, T.1
Nishimoto, N.2
Kishimoto, T.3
-
175
-
-
0027461913
-
Interleukin-2 receptor-directed therapies: Antibody-or cytokine-based targeting molecules
-
Strop, T. B., Kelley, V. R., Murphy, J. R., Nichols, J. & Woodworth, T. G. Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules. Annu. Rev. Med. 44, 343-353 (1993).
-
(1993)
Annu. Rev. Med.
, vol.44
, pp. 343-353
-
-
Strop, T.B.1
Kelley, V.R.2
Murphy, J.R.3
Nichols, J.4
Woodworth, T.G.5
-
176
-
-
0023718514
-
Immunosuppression of collagen-induced arthritis in mice with an anti-IL-2 receptor antibody
-
Banerjee, S., Wei, B. Y., Hillman, K., Luthra, H. S. & David, C. S. Immunosuppression of collagen-induced arthritis in mice with an anti-IL-2 receptor antibody J. Immunol. 141, 1150-1154 (1988).
-
(1988)
J. Immunol.
, vol.141
, pp. 1150-1154
-
-
Banerjee, S.1
Wei, B.Y.2
Hillman, K.3
Luthra, H.S.4
David, C.S.5
-
177
-
-
0036889625
-
Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene
-
Shao, R. H., Tian, X., Gorgun, G., Urbano, A. G., & Foss, F. M. Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene. Leuk. Res. 26, 1077-1083 (2002).
-
(2002)
Leuk. Res.
, vol.26
, pp. 1077-1083
-
-
Shao, R.H.1
Tian, X.2
Gorgun, G.3
Urbano, A.G.4
Foss, F.M.5
-
178
-
-
0028990380
-
Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis
-
Gottlieb, S. L. et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med. 1, 442-447 (1995).
-
(1995)
Nature Med.
, vol.1
, pp. 442-447
-
-
Gottlieb, S.L.1
-
179
-
-
0029164940
-
Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension
-
Moreland, L. W. et al. Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension. Arthritis Rheum. 38, 1177-1186 (1995).
-
(1995)
Arthritis Rheum.
, vol.38
, pp. 1177-1186
-
-
Moreland, L.W.1
-
180
-
-
0035166183
-
Role of anti-interleukin-2 receptor antibodies in kidney transplantation
-
Cibrilk, D. M., Kaplan, B. & Meier-Kriesche, H. U. Role of anti-interleukin-2 receptor antibodies in kidney transplantation. BioDrugs. 15, 655-666 (2001).
-
(2001)
BioDrugs
, vol.15
, pp. 655-666
-
-
Cibrilk, D.M.1
Kaplan, B.2
Meier-Kriesche, H.U.3
-
181
-
-
0031042456
-
Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis
-
McInnes, I. B., Leung, B. P., Sturrock, R. D., Field, M. & Liew, F. Y. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nature Med. 3, 189-195 (1997).
-
(1997)
Nature Med.
, vol.3
, pp. 189-195
-
-
McInnes, I.B.1
Leung, B.P.2
Sturrock, R.D.3
Field, M.4
Liew, F.Y.5
-
182
-
-
0032103993
-
Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: A role for IL-15 in development of antigen-induced immunopathology
-
Ruchatz, H., Leung, B. P., Wei, X. Q., McInnes, I. B. & Liew, F. Y. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J. Immunol. 160, 5654-5660 (1998).
-
(1998)
J. Immunol.
, vol.160
, pp. 5654-5660
-
-
Ruchatz, H.1
Leung, B.P.2
Wei, X.Q.3
McInnes, I.B.4
Liew, F.Y.5
-
183
-
-
0033041866
-
Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis
-
Butler, D. M., Malfait A. M., Maini, R. N., Brennan, F. M. & Feldmann, M. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur. J. Immunol. 29, 2205-2212 (1999).
-
(1999)
Eur. J. Immunol.
, vol.29
, pp. 2205-2212
-
-
Butler, D.M.1
Malfait, A.M.2
Maini, R.N.3
Brennan, F.M.4
Feldmann, M.5
-
184
-
-
0032743708
-
A proinflammatory role for IL-18 in rheumatoid arthritis
-
Gracie, J. A. et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J. Clin. Invest 104, 1393-1401 (1999).
-
(1999)
J. Clin. Invest.
, vol.104
, pp. 1393-1401
-
-
Gracie, J.A.1
-
185
-
-
0024490105
-
Endotoxin-induced serum factor that stimulates γ-interferon production
-
Nakamura, K., Okamura, H., Wada, M., Nagata, K. & Tamura, T. Endotoxin-induced serum factor that stimulates γ-interferon production. Infect. Immun. 57, 590-595 (1989).
-
(1989)
Infect. Immun.
, vol.57
, pp. 590-595
-
-
Nakamura, K.1
Okamura, H.2
Wada, M.3
Nagata, K.4
Tamura, T.5
-
186
-
-
0035173776
-
Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18
-
Wei, X. Q., Leung, B. P., Arthur, H. M., McInnes, I. B. & Liew, F. Y. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J. Immunol. 166, 517-521 (2001).
-
(2001)
J. Immunol.
, vol.166
, pp. 517-521
-
-
Wei, X.Q.1
Leung, B.P.2
Arthur, H.M.3
McInnes, I.B.4
Liew, F.Y.5
-
187
-
-
0035664487
-
Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis
-
Plater-Zyberk, C. et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J. Clin. Invest. 108, 1825-1832 (2001).
-
(2001)
J. Clin. Invest.
, vol.108
, pp. 1825-1832
-
-
Plater-Zyberk, C.1
-
188
-
-
0032939156
-
Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium
-
Chabaud, M. et al. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 42, 963-970 (1999).
-
(1999)
Arthritis Rheum.
, vol.42
, pp. 963-970
-
-
Chabaud, M.1
-
189
-
-
0033136695
-
NF-κB-inducing kinase is a common mediator of IL-17-, TNF-α-,and IL-1β-induced chemokine promoter activation in intestinal epithelial cells
-
Awane, M., Andres, P. G., Li, D. J. & Reinecker, H. C. NF-κB-inducing kinase is a common mediator of IL-17-, TNF-α-,and IL-1β-induced chemokine promoter activation in intestinal epithelial cells. J. Immunol. 162, 5337-5344 (1999).
-
(1999)
J. Immunol.
, vol.162
, pp. 5337-5344
-
-
Awane, M.1
Andres, P.G.2
Li, D.J.3
Reinecker, H.C.4
-
190
-
-
0035078953
-
Modulation of TIMP-1 synthesis by antiinflammatory cytokines and prostaglandin E2 in interleukin 17 stimulated human monocytes/macrophages
-
Jovanovic, D. V. et al. Modulation of TIMP-1 synthesis by antiinflammatory cytokines and prostaglandin E2 in interleukin 17 stimulated human monocytes/macrophages. J. Rheumatol. 28, 712-718 (2001).
-
(2001)
J. Rheumatol.
, vol.28
, pp. 712-718
-
-
Jovanovic, D.V.1
-
191
-
-
0034966563
-
The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model
-
Chibaud M. & Miossec, P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum. 44, 1293-1303 (2001).
-
(2001)
Arthritis Rheum.
, vol.44
, pp. 1293-1303
-
-
Chibaud, M.1
Miossec, P.2
-
192
-
-
0242293743
-
-
Smolen, J. S. & Lipsky, P. E. (eds.) (Martin Dunitz, London-New York)
-
Szekanecz, Z., Kim, J. & Koch, A. E. In Targeted Therapies in Rheumatology. Smolen, J. S. & Lipsky, P. E. (eds.) 345-357 (Martin Dunitz, London-New York, 2003).
-
(2003)
Targeted Therapies in Rheumatology
, pp. 345-357
-
-
Szekanecz, Z.1
Kim, J.2
Koch, A.E.3
-
193
-
-
0034568503
-
CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis
-
Zapico,-I. et al. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun. 1, 288-289 (2000).
-
(2000)
Genes Immun.
, vol.1
, pp. 288-289
-
-
Zapico, I.1
-
194
-
-
0036803279
-
Chemokines, chemokine receptors and small-molecule antagonists: Recent developments
-
Onuffer, J. J. & Horuk, R. Chemokines, chemokine receptors and small-molecule antagonists: recent developments, Trends Pharmacol. Sci. 23, 459-467 (2002).
-
(2002)
Trends Pharmacol. Sci.
, vol.23
, pp. 459-467
-
-
Onuffer, J.J.1
Horuk, R.2
-
195
-
-
0035865316
-
Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: A new strategy in the treatment of chronic inflammatory diseases and HIV
-
Bruhl, H., Cihak, J., Stangassinger, M., Schlondorff, D. & Mack, M. Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV J. Immunol. 166, 2420-2426 (2001).
-
(2001)
J. Immunol.
, vol.166
, pp. 2420-2426
-
-
Bruhl, H.1
Cihak, J.2
Stangassinger, M.3
Schlondorff, D.4
Mack, M.5
-
196
-
-
0034814370
-
Neutralization of vascular endothelial growth factor prevents collagen- induced arthritis and ameliorates established disease in mice
-
Sone, H. et al. Neutralization of vascular endothelial growth factor prevents collagen- induced arthritis and ameliorates established disease in mice. Biochem. Biophys. Res. Commun. 281, 562-568 (2001).
-
(2001)
Biochem. Biophys. Res. Commun.
, vol.281
, pp. 562-568
-
-
Sone, H.1
-
198
-
-
0037143764
-
VEGF-Trap: A VEGF blocker with potent anti-tumor effects
-
Holash, J. et al. VEGF-Trap: a VEGF blocker with potent anti-tumor effects. Proc. Natl Acad. Sci. USA 99, 11393-11398 (2002).
-
(2002)
Proc. Natl. Acad. Sci. USA
, vol.99
, pp. 11393-11398
-
-
Holash, J.1
-
199
-
-
0036913264
-
Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4
-
Tarner, I. H. et al. Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4. Clin. Immunol. 105, 304-314 (2002).
-
(2002)
Clin. Immunol.
, vol.105
, pp. 304-314
-
-
Tarner, I.H.1
-
200
-
-
0002130296
-
rHu IL-4 in subjects with active rheumatoid arthritis (RA): A phase I dose escalating safety study
-
van den Bosch, F. et al. rHu IL-4 in subjects with active rheumatoid arthritis (RA): a phase I dose escalating safety study. Arthritis Rheum. 41, S56 (1998).
-
(1998)
Arthritis Rheum.
, vol.41
-
-
van den Bosch, F.1
-
201
-
-
0002492007
-
rHuIL-10 (Tenovil) plus methotrexate (MTX) in active rheumatoid arthritis: A phase I/II study
-
Weinblatt, M. E. et al. rHuIL-10 (Tenovil) plus methotrexate (MTX) in active rheumatoid arthritis: A phase I/II study. Arthritis Rheum. 42 S170 (1999).
-
(1999)
Arthritis Rheum.
, vol.42
-
-
Weinblatt, M.E.1
-
202
-
-
0000428990
-
rHu IL-10 in jubjects with active rheumatoid arthritis: A phase I cytokine response study
-
Maini, R. N. et al. rHu IL-10 in jubjects with active rheumatoid arthritis: A phase I cytokine response study. Arthritis Rheum. 41, S224 (1998).
-
(1998)
Arthritis Rheum.
, vol.41
-
-
Maini, R.N.1
-
203
-
-
0036667140
-
Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines
-
van Roon, J. A., Bijlsma, J. W. & Lafeber, F. P. Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines. Curr. Opin. Investig. Drugs 3, 1011-1016 (2002).
-
(2002)
Curr. Opin. Investig. Drugs
, vol.3
, pp. 1011-1016
-
-
van Roon, J.A.1
Bijlsma, J.W.2
Lafeber, F.P.3
-
204
-
-
0034280613
-
Clinical efficacy of rhIL-11
-
Reynolds, C. H. Clinical efficacy of rhIL-11. Oncology (Huntingt) 14, 32-40 (2000).
-
(2000)
Oncology (Huntingt)
, vol.14
, pp. 32-40
-
-
Reynolds, C.H.1
-
205
-
-
17844403234
-
Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis
-
Moreland, L. et al. Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res. 3, 247-252,(2001).
-
(2001)
Arthritis Res.
, vol.3
, pp. 247-252
-
-
Moreland, L.1
-
206
-
-
0029797868
-
Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13
-
Bessis, N. et al. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13 Eur. J. Immunol. 26, 2399-2403 (1996).
-
(1996)
Eur. J. Immunol.
, vol.26
, pp. 2399-2403
-
-
Bessis, N.1
-
207
-
-
0034284226
-
Reduction of inflammatory cytokines and prostaglandin E2 by IL-13 gene therapy in rheumatoid arthritis synovium
-
Woods, J. M. et al. Reduction of inflammatory cytokines and prostaglandin E2 by IL-13 gene therapy in rheumatoid arthritis synovium. J. Immunol. 165, 2755-2763 (2000).
-
(2000)
J. Immunol.
, vol.165
, pp. 2755-2763
-
-
Woods, J.M.1
-
208
-
-
0026767264
-
Recombinant human interferon-γ in the treatment of rheumatoid arthritis: Double blind placebo controlled study
-
Machold, K. P., Neumann, K. & Smolen, J. S. Recombinant human interferon-γ in the treatment of rheumatoid arthritis: double blind placebo controlled study. Ann. Rheum.Dis. 51, 1039-1043(1992).
-
(1992)
Ann. Rheum.Dis.
, vol.51
, pp. 1039-1043
-
-
Machold, K.P.1
Neumann, K.2
Smolen, J.S.3
-
209
-
-
0025239792
-
Prospective two-year followup of recombinant interferon-γ in rheumatoid arthritis
-
Cannon, G. W. et al. Prospective two-year followup of recombinant interferon-γ in rheumatoid arthritis. J. Rheumatol. 17, 304-310 (1990).
-
(1990)
J. Rheumatol.
, vol.17
, pp. 304-310
-
-
Cannon, G.W.1
-
210
-
-
0027731536
-
Prospective 5-year followup of recombinant interferon-γ in rheumatoid arthritis
-
Cannon, G. W. et al. Prospective 5-year followup of recombinant interferon-γ in rheumatoid arthritis. J. Rheumatol. 20, 1867-1873 (1993).
-
(1993)
J. Rheumatol.
, vol.20
, pp. 1867-1873
-
-
Cannon, G.W.1
-
211
-
-
0026316320
-
Induction of systemic lupus erythematosus by interferon-γ in a patient with rheumatoid arthritis
-
Graninger, W. B. et al. Induction of systemic lupus erythematosus by interferon-γ in a patient with rheumatoid arthritis. J. Rheumatol. 18, 1621-1622 (1991).
-
(1991)
J. Rheumatol.
, vol.18
, pp. 1621-1622
-
-
Graninger, W.B.1
-
212
-
-
0036796835
-
Repeat-cycle study of high-dose intravenous 4162W94 ani-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo- controlled trial
-
Choy, E. H. et al. Repeat-cycle study of high-dose intravenous 4162W94 ani-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo- controlled trial. Rheumatology (Oxford) 41, 1142-1148 (2002).
-
(2002)
Rheumatology (Oxford)
, vol.41
, pp. 1142-1148
-
-
Choy, E.H.1
-
213
-
-
8944229691
-
A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis
-
The Xoma RA Investigator Group
-
Olsen, N. J. et al. A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum. 39, 1102-1108 (1996).
-
(1996)
Arthritis Rheum.
, vol.39
, pp. 1102-1108
-
-
Olsen, N.J.1
-
214
-
-
0033062691
-
CD28/CTLA-4 and CD80/CD86 families: Signaling and function
-
Slavik, J. M., Hutchcroft, J. E. & Bierer, B. E. CD28/CTLA-4 and CD80/CD86 families: signaling and function. Immunol. Res. 19, 1-24 (1999).
-
(1999)
Immunol. Res.
, vol.19
, pp. 1-24
-
-
Slavik, J.M.1
Hutchcroft, J.E.2
Bierer, B.E.3
-
215
-
-
0038386405
-
A multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and preliminary clinical activity of multiple doses of CTLA4Ig and LEA294 administered intravenously to subjects with rheumatoid arthritis
-
Moreland, L. W. et al. A multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and preliminary clinical activity of multiple doses of CTLA4Ig and LEA294 administered intravenously to subjects with rheumatoid arthritis. Arthritis Rheum. 44, S274 (2001).
-
(2001)
Arthritis Rheum.
, vol.44
-
-
Moreland, L.W.1
-
216
-
-
0013304005
-
A phase 2B multi-center randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of two different doses of CTLA4Ig administered intravenously to subjects with active rheumatoid arthritis while receiving methotrexate
-
Kremer, J. et al. A phase 2B multi-center randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of two different doses of CTLA4Ig administered intravenously to subjects with active rheumatoid arthritis while receiving methotrexate. Arthritis Rheum. 46, S203 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
-
-
Kremer, J.1
-
217
-
-
0013218378
-
A pilot, multi-center, randomized, double blind, placebo controlled study of a co-stimulation blocker CTLA4Ig (2mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis
-
Weinblatt, M. E. et al. A pilot, multi-center, randomized, double blind, placebo controlled study of a co-stimulation blocker CTLA4Ig (2mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis. Arthritis Rheum. 46 S204 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
-
-
Weinblatt, M.E.1
-
218
-
-
0034811018
-
Treatment of autoimmunity by inhibition of T cell co-stimulation
-
Dalkh, D. I. & Wofsy D. Treatment of autoimmunity by inhibition of T cell co-stimulation. Adv. Exp. Med. Biol. 490, 113-117 (2001).
-
(2001)
Adv. Exp. Med. Biol.
, vol.490
, pp. 113-117
-
-
Dalkh, D.I.1
Wofsy, D.2
-
219
-
-
0035129767
-
The CD40/CD154 receptor/ligand dyad
-
Schonbeck, U. & Libby, P. The CD40/CD154 receptor/ligand dyad. Cell Mol. Life Sci. 58, 4-43 (2001).
-
(2001)
Cell Mol. Life Sci.
, vol.58
, pp. 4-43
-
-
Schonbeck, U.1
Libby, P.2
-
220
-
-
0036170440
-
Activation and inhibition of lymphocytes by co-stimulation
-
Frauwirth, K. A. & Thompson, C. B. Activation and inhibition of lymphocytes by co-stimulation. J. Clin. Invest. 109, 295-299 (2002).
-
(2002)
J. Clin. Invest.
, vol.109
, pp. 295-299
-
-
Frauwirth, K.A.1
Thompson, C.B.2
-
221
-
-
0036676817
-
Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells
-
De Vita, S. et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells, Arthritis Rheum. 46, 2029-2033 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
, pp. 2029-2033
-
-
De Vita, S.1
-
222
-
-
0038386557
-
Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: A randomized, placebo-controlled trial in patients with rheumatoid arthritis
-
Edwards, J. C. W. et al. Efficacy and safety of rituximab, a B-cell targeted chimeric monoclonal antibody: a randomized, placebo-controlled trial in patients with rheumatoid arthritis. Arthritis Rheum. 46, S197 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
-
-
Edwards, J.C.W.1
-
223
-
-
0033746843
-
Immunoadsorption for the treatment of rheumatoid arthritis: Final results of a randomized trial
-
Proscribe Trial Investigators
-
Furst, D., Felson, D., Thoren, G. & Gendreau, R. M. Immunoadsorption for the treatment of rheumatoid arthritis: final results of a randomized trial. Proscribe Trial Investigators. Ther. Apher. 4, 363-373 (2000).
-
(2000)
Ther. Apher.
, vol.4
, pp. 363-373
-
-
Furst, D.1
Felson, D.2
Thoren, G.3
Gendreau, R.M.4
-
225
-
-
0037234358
-
Coordinate expression of activating Fc gamma receptors I and III and inhibiting Fc gamma receptor type II in the determination of joint inflammation and cartilage destruction during immune complex-mediated arthritis
-
Nabbe, K. C. et al, Coordinate expression of activating Fc gamma receptors I and III and inhibiting Fc gamma receptor type II in the determination of joint inflammation and cartilage destruction during immune complex-mediated arthritis. Arthritis Rheum. 48, 255-265 (2003).
-
(2003)
Arthritis Rheum.
, vol.48
, pp. 255-265
-
-
Nabbe, K.C.1
-
227
-
-
0242293744
-
-
Smolen, J. S. & Lipsky, P. E. (eds.), (Martin Dunitz, London-New York)
-
Holers, V. M. In Targeted Therapies in Rheumatology. Smolen, J. S. & Lipsky, P. E. (eds.), pp. 167-180 (Martin Dunitz, London-New York, 2003).
-
(2003)
Targeted Therapies in Rheumatology
, pp. 167-180
-
-
Holers, V.M.1
-
228
-
-
0034190238
-
Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades
-
Hubbard, A. K. & Rothlein, R. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radio. Biol. Med. 28, 1379-1386 (2000).
-
(2000)
Free Radio. Biol. Med.
, vol.28
, pp. 1379-1386
-
-
Hubbard, A.K.1
Rothlein, R.2
-
229
-
-
0028355977
-
Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1
-
Kavanaugh, A. F. et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 37, 992-999 (1994).
-
(1994)
Arthritis Rheum.
, vol.37
, pp. 992-999
-
-
Kavanaugh, A.F.1
-
230
-
-
0029739255
-
A phase I/II open label study of the safety and efficacy of an anti- ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis
-
Kavanaugh, A. F. et al. A phase I/II open label study of the safety and efficacy of an anti- ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J. Rheumatol. 23, 1338-1344 (1996).
-
(1996)
J. Rheumatol.
, vol.23
, pp. 1338-1344
-
-
Kavanaugh, A.F.1
-
231
-
-
0030911156
-
Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody
-
Kavanaugh, A. F., Schulze-Koops, H., Davis, L. S. & Lipsky, P. E. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum. 40, 849-853 (1997).
-
(1997)
Arthritis Rheum.
, vol.40
, pp. 849-853
-
-
Kavanaugh, A.F.1
Schulze-Koops, H.2
Davis, L.S.3
Lipsky, P.E.4
-
233
-
-
0034695921
-
Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength
-
Chellaiah, M. et al. Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength. J. Cell Biol. 148, 665-678 (2000).
-
(2000)
J. Cell Biol.
, vol.148
, pp. 665-678
-
-
Chellaiah, M.1
-
234
-
-
0035150588
-
Disease-modifying activity of SB 273005, an orally active, nonpeptide αVβ3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis
-
Badger, A. M. et al. Disease-modifying activity of SB 273005, an orally active, nonpeptide αVβ3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum. 44, 128-137 (2001).
-
(2001)
Arthritis Rheum.
, vol.44
, pp. 128-137
-
-
Badger, A.M.1
-
235
-
-
0036839554
-
Integrin αVβ3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases
-
Wilder, R. L. Integrin αVβ3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. 61 S2, ii96-ii99 (2002).
-
(2002)
Ann. Rheum. Dis.
, vol.61
, Issue.S2
-
-
Wilder, R.L.1
-
236
-
-
0035746070
-
Anti-adhesion antibodies efalizumab, a humanized anti-CD11 a monoclonal antibody
-
Dedrick, R. L., Walicke, P. & Garovoy, M. Anti-adhesion antibodies efalizumab, a humanized anti-CD11 a monoclonal antibody. Transol. Immunol. 9, 181-186 (2002).
-
(2002)
Transol. Immunol.
, vol.9
, pp. 181-186
-
-
Dedrick, R.L.1
Walicke, P.2
Garovoy, M.3
-
237
-
-
0037413468
-
Natalizumab for active Crohn's disease
-
Ghosh, S. et al. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348, 24-32 (2003).
-
(2003)
N. Engl. J. Med.
, vol.348
, pp. 24-32
-
-
Ghosh, S.1
-
238
-
-
0037413467
-
A controlled trial of natalizumab for relapsing multiple sclerosis
-
Miller, D. H. et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15-23 (2003).
-
(2003)
N. Engl. J. Med.
, vol.348
, pp. 15-23
-
-
Miller, D.H.1
-
239
-
-
0036822279
-
Alefacept treatment in psoriatic arthritis: Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis
-
Kraan, M. C. et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 46, 2776-2784 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
, pp. 2776-2784
-
-
Kraan, M.C.1
-
240
-
-
0036895587
-
A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis
-
Krueger, G. G. et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. 47, 821-833 (2002).
-
(2002)
J. Am. Acad. Dermatol.
, vol.47
, pp. 821-833
-
-
Krueger, G.G.1
-
241
-
-
0036377106
-
Biological aspects of signal transduction by cell adhesion receptors
-
Alahari, S. K., Reddig, P. J. & Juliano, R. L. Biological aspects of signal transduction by cell adhesion receptors. Int. Rev. Cytol. 220, 145-184 (2002).
-
(2002)
Int. Rev. Cytol.
, vol.220
, pp. 145-184
-
-
Alahari, S.K.1
Reddig, P.J.2
Juliano, R.L.3
-
242
-
-
0034948339
-
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site
-
Weitz-Schmidt, G. et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Med. 7, 687-692 (2001).
-
(2001)
Nature Med.
, vol.7
, pp. 687-692
-
-
Weitz-Schmidt, G.1
-
243
-
-
0036780681
-
Toll-like receptors as potential therapeutic targets for multiple diseases
-
Zuany-Amorim, C., Hastewell, J. & Walker, C. Toll-like receptors as potential therapeutic targets for multiple diseases. Nature Rev. Drug Discov. 1, 797-807 (2002).
-
(2002)
Nature Rev. Drug Discov.
, vol.1
, pp. 797-807
-
-
Zuany-Amorim, C.1
Hastewell, J.2
Walker, C.3
-
244
-
-
0037378466
-
Expression and regulation of toll-like receptor 2 in rheumatoid arthritis synovium
-
Seibl, R. et al. Expression and regulation of toll-like receptor 2 in rheumatoid arthritis synovium. Am. J. Pathol. 162, 1221-1227 (2003).
-
(2003)
Am. J. Pathol.
, vol.162
, pp. 1221-1227
-
-
Seibl, R.1
-
245
-
-
0031894140
-
Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis
-
Gravallese, E. M. et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 152, 943-951 (1998).
-
(1998)
Am. J. Pathol.
, vol.152
, pp. 943-951
-
-
Gravallese, E.M.1
-
246
-
-
0036898425
-
Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis
-
Bolon, B. et al. Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. Arthritis Rheum. 46, 3121-3135 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
, pp. 3121-3135
-
-
Bolon, B.1
-
247
-
-
0036185343
-
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin
-
Redlich K et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 46, 785-792 (2002).
-
(2002)
Arthritis Rheum.
, vol.46
, pp. 785-792
-
-
Redlich, K.1
-
248
-
-
0033581952
-
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
-
Kong, Y. Y. et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304-309 (1999).
-
(1999)
Nature
, vol.402
, pp. 304-309
-
-
Kong, Y.Y.1
-
249
-
-
0035153246
-
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis
-
Pettit, A. R. et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 159, 1689-1699 (2001).
-
(2001)
Am. J. Pathol.
, vol.159
, pp. 1689-1699
-
-
Pettit, A.R.1
-
250
-
-
0035139584
-
The effect of a single dose of osteoprotegerin in postmenopausal women
-
Bekker, P. J. et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16, 348-360 (2001).
-
(2001)
J. Bone Miner. Res.
, vol.16
, pp. 348-360
-
-
Bekker, P.J.1
-
251
-
-
0036250129
-
Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines
-
Heikkila, P. et al. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 13, 245-254 (2002).
-
(2002)
Anticancer Drugs
, vol.13
, pp. 245-254
-
-
Heikkila, P.1
-
252
-
-
0030007961
-
Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial
-
Eggelmeijer, F. et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum. 39, 396-402 (1996).
-
(1996)
Arthritis Rheum.
, vol.39
, pp. 396-402
-
-
Eggelmeijer, F.1
-
253
-
-
0026561081
-
The work of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials
-
Smolen, J. S. The work of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials. Br. J. Rheumatol. 31, 219-220 (1992).
-
(1992)
Br. J. Rheumatol.
, vol.31
, pp. 219-220
-
-
Smolen, J.S.1
-
254
-
-
0027238592
-
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
-
Felson, D. T. et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 36, 729-740 (1993).
-
(1993)
Arthritis Rheum.
, vol.36
, pp. 729-740
-
-
Felson, D.T.1
-
255
-
-
0033019626
-
ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis
-
van Gestel, A. M. et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis. J. Rheumatol. 26, 705-711 (1999).
-
(1999)
J. Rheumatol.
, vol.26
, pp. 705-711
-
-
van Gestel, A.M.1
-
256
-
-
0034123087
-
Treatment with LEF slows radiographic progression of rheumatoid arthritis. Results from three randomized controlled trials of LEF in patients with active rheumatoid arthritis
-
Sharp, J. T., Strand, V., Leung, H., Hurley, F. & Loew-Friedrich, I. Treatment with LEF slows radiographic progression of rheumatoid arthritis. Results from three randomized controlled trials of LEF in patients with active rheumatoid arthritis. Arthritis Rheum. 43, 495-505 (2000).
-
(2000)
Arthritis Rheum.
, vol.43
, pp. 495-505
-
-
Sharp, J.T.1
Strand, V.2
Leung, H.3
Hurley, F.4
Loew-Friedrich, I.5
|